Article

Bristol-Myers Sues Merck Over US Immunotherapy Patent

"Merck is threatening to exploit that invention," known as immunotherapy, with a later-developed method of treatment, in violation of a May 20 patent, Bristol-Myers said in a lawsuit filed yesterday in federal court in Wilmington, Delaware. The New York-based company is seeking unspecified damages.

“Merck is threatening to exploit that invention,” known as immunotherapy, with a later-developed method of treatment, in violation of a May 20 patent, Bristol-Myers said in a lawsuit filed yesterday in federal court in Wilmington, Delaware. The New York-based company is seeking unspecified damages.

Merck yesterday won US approval for Keytruda, an immunotherapy chemically known as pembrolizumab, to treat advanced melanoma, the deadliest version of skin cancer. Bristol-Myers and Merck have been in a race with

and

, who are also working on similar treatments, and the emerging class of drugs is seen as a new chapter in cancer therapy, with the potential to be applied to multiple forms of the disease.

Read the full story:

Roche Holding AG (ROG)Novartis AG (NOVN)

http://bloom.bg/1oOssxN

Source: Bloomberg

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Richard Lafayette, MD, FACP, Stanford
Eric Lander, MD
Dr Ashley Yocum
Lorna Warwick
Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo